Robbie Marcus
Stock Analyst at JP Morgan
(4.19)
# 522
Out of 4,479 analysts
93
Total ratings
62.67%
Success rate
9.07%
Average return
Main Sectors:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENOV Enovis | Initiates: Neutral | $53 | $44.71 | +18.54% | 1 | Jun 13, 2024 | |
| TMCI Treace Medical Concepts | Downgrades: Neutral | $15 → $8 | $6.63 | +20.66% | 2 | May 8, 2024 | |
| ATRC AtriCure | Maintains: Overweight | $42 → $34 | $22.39 | +51.85% | 3 | May 2, 2024 | |
| SILK Silk Road Medical | Maintains: Neutral | $19 → $21 | $27.02 | -22.28% | 3 | May 1, 2024 | |
| CVRX CVRx, Inc. | Downgrades: Neutral | $36 → $13 | $11.78 | +10.36% | 5 | May 1, 2024 | |
| CNMD CONMED | Maintains: Overweight | $115 → $75 | $67.04 | +11.87% | 4 | Apr 25, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $72 → $82 | $76.55 | +7.12% | 4 | Apr 25, 2024 | |
| COO The Cooper Companies | Upgrades: Overweight | $100 → $120 | $86.51 | +38.71% | 3 | Mar 13, 2024 | |
| NPCE NeuroPace | Maintains: Overweight | $9 → $17 | $7.23 | +135.13% | 3 | Mar 12, 2024 | |
| RXST RxSight | Maintains: Overweight | $40 → $62 | $57.04 | +8.70% | 3 | Feb 29, 2024 | |
| PODD Insulet | Maintains: Overweight | $190 → $225 | $197.19 | +14.10% | 3 | Feb 23, 2024 | |
| PEN Penumbra | Downgrades: Neutral | $284 → $250 | $175.99 | +42.05% | 4 | Feb 23, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $115 → $125 | $106.27 | +17.62% | 3 | Feb 9, 2024 | |
| BAX Baxter International | Maintains: Neutral | $38 → $44 | $32.85 | +33.94% | 6 | Feb 9, 2024 | |
| ZIMV ZimVie | Maintains: Neutral | $10 → $16 | $18.14 | -11.80% | 3 | Dec 20, 2023 | |
| INGN Inogen | Maintains: Underweight | $8 → $7 | $7.67 | -8.74% | 5 | Nov 8, 2023 | |
| NVRO Nevro | Maintains: Neutral | $23 → $18 | $8.35 | +115.57% | 4 | Nov 2, 2023 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $340 → $181 | $134.25 | +34.82% | 4 | Oct 17, 2023 | |
| EW Edwards Lifesciences | Maintains: Overweight | $95 → $100 | $91.23 | +9.61% | 2 | Jul 27, 2023 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $335 → $365 | $438.81 | -16.82% | 3 | Jul 21, 2023 | |
| IART Integra LifeSciences Holdings | Downgrades: Underweight | $56 → $43 | $29.19 | +47.31% | 4 | May 24, 2023 | |
| SYK Stryker | Maintains: Overweight | $285 → $315 | $334.30 | -5.77% | 3 | May 2, 2023 | |
| BLCO Bausch + Lomb | Maintains: Neutral | $15 → $17 | $14.66 | +15.96% | 2 | Feb 23, 2023 | |
| BVS Bioventus | Downgrades: Underweight | n/a | $5.78 | - | 2 | Nov 9, 2022 | |
| ABT Abbott Laboratories | Maintains: Overweight | $125 → $118 | $103.20 | +14.34% | 5 | Oct 20, 2022 | |
| UTRS Minerva Surgical | Downgrades: Underweight | n/a | $1.48 | - | 2 | Aug 10, 2022 | |
| IRTC iRhythm Technologies | Maintains: Overweight | $116 → $156 | $98.61 | +58.20% | 2 | Jan 27, 2022 | |
| MDT Medtronic | Downgrades: Neutral | n/a | $77.37 | - | 2 | Dec 17, 2021 | |
| AFIB Acutus Medical | Downgrades: Underweight | n/a | $0.04 | - | 2 | Nov 12, 2021 | |
| GKOS Glaukos | Downgrades: Neutral | n/a | $118.98 | - | 1 | Feb 28, 2020 |
Enovis
Jun 13, 2024
Initiates: Neutral
Price Target: $53
Current: $44.71
Upside: +18.54%
Treace Medical Concepts
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $6.63
Upside: +20.66%
AtriCure
May 2, 2024
Maintains: Overweight
Price Target: $42 → $34
Current: $22.39
Upside: +51.85%
Silk Road Medical
May 1, 2024
Maintains: Neutral
Price Target: $19 → $21
Current: $27.02
Upside: -22.28%
CVRx, Inc.
May 1, 2024
Downgrades: Neutral
Price Target: $36 → $13
Current: $11.78
Upside: +10.36%
CONMED
Apr 25, 2024
Maintains: Overweight
Price Target: $115 → $75
Current: $67.04
Upside: +11.87%
Boston Scientific
Apr 25, 2024
Maintains: Overweight
Price Target: $72 → $82
Current: $76.55
Upside: +7.12%
The Cooper Companies
Mar 13, 2024
Upgrades: Overweight
Price Target: $100 → $120
Current: $86.51
Upside: +38.71%
NeuroPace
Mar 12, 2024
Maintains: Overweight
Price Target: $9 → $17
Current: $7.23
Upside: +135.13%
RxSight
Feb 29, 2024
Maintains: Overweight
Price Target: $40 → $62
Current: $57.04
Upside: +8.70%
Insulet
Feb 23, 2024
Maintains: Overweight
Price Target: $190 → $225
Current: $197.19
Upside: +14.10%
Penumbra
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $175.99
Upside: +42.05%
Zimmer Biomet Holdings
Feb 9, 2024
Maintains: Neutral
Price Target: $115 → $125
Current: $106.27
Upside: +17.62%
Baxter International
Feb 9, 2024
Maintains: Neutral
Price Target: $38 → $44
Current: $32.85
Upside: +33.94%
ZimVie
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $18.14
Upside: -11.80%
Inogen
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $7.67
Upside: -8.74%
Nevro
Nov 2, 2023
Maintains: Neutral
Price Target: $23 → $18
Current: $8.35
Upside: +115.57%
Inspire Medical Systems
Oct 17, 2023
Maintains: Overweight
Price Target: $340 → $181
Current: $134.25
Upside: +34.82%
Edwards Lifesciences
Jul 27, 2023
Maintains: Overweight
Price Target: $95 → $100
Current: $91.23
Upside: +9.61%
Intuitive Surgical
Jul 21, 2023
Maintains: Overweight
Price Target: $335 → $365
Current: $438.81
Upside: -16.82%
Integra LifeSciences Holdings
May 24, 2023
Downgrades: Underweight
Price Target: $56 → $43
Current: $29.19
Upside: +47.31%
Stryker
May 2, 2023
Maintains: Overweight
Price Target: $285 → $315
Current: $334.30
Upside: -5.77%
Bausch + Lomb
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $14.66
Upside: +15.96%
Bioventus
Nov 9, 2022
Downgrades: Underweight
Price Target: n/a
Current: $5.78
Upside: -
Abbott Laboratories
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $103.20
Upside: +14.34%
Minerva Surgical
Aug 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.48
Upside: -
iRhythm Technologies
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $98.61
Upside: +58.20%
Medtronic
Dec 17, 2021
Downgrades: Neutral
Price Target: n/a
Current: $77.37
Upside: -
Acutus Medical
Nov 12, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.04
Upside: -
Glaukos
Feb 28, 2020
Downgrades: Neutral
Price Target: n/a
Current: $118.98
Upside: -